JP2020511536A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511536A5
JP2020511536A5 JP2019572352A JP2019572352A JP2020511536A5 JP 2020511536 A5 JP2020511536 A5 JP 2020511536A5 JP 2019572352 A JP2019572352 A JP 2019572352A JP 2019572352 A JP2019572352 A JP 2019572352A JP 2020511536 A5 JP2020511536 A5 JP 2020511536A5
Authority
JP
Japan
Prior art keywords
alkyl
solvate
acceptable salt
pharmaceutically acceptable
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019572352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511536A (ja
JP7178375B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022049 external-priority patent/WO2018169880A1/en
Publication of JP2020511536A publication Critical patent/JP2020511536A/ja
Publication of JP2020511536A5 publication Critical patent/JP2020511536A5/ja
Priority to JP2022014178A priority Critical patent/JP7781660B2/ja
Priority to JP2022105683A priority patent/JP7440572B2/ja
Application granted granted Critical
Publication of JP7178375B2 publication Critical patent/JP7178375B2/ja
Priority to JP2024020785A priority patent/JP2024056887A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019572352A 2017-03-13 2018-03-12 デュアルmagl及びfaahインヒビター Active JP7178375B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022014178A JP7781660B2 (ja) 2017-03-13 2022-02-01 デュアルmagl及びfaahインヒビター
JP2022105683A JP7440572B2 (ja) 2017-03-13 2022-06-30 デュアルmagl及びfaahインヒビター
JP2024020785A JP2024056887A (ja) 2017-03-13 2024-02-15 デュアルmagl及びfaahインヒビター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470830P 2017-03-13 2017-03-13
US62/470,830 2017-03-13
PCT/US2018/022049 WO2018169880A1 (en) 2017-03-13 2018-03-12 Dual magl and faah inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022014178A Division JP7781660B2 (ja) 2017-03-13 2022-02-01 デュアルmagl及びfaahインヒビター
JP2022105683A Division JP7440572B2 (ja) 2017-03-13 2022-06-30 デュアルmagl及びfaahインヒビター

Publications (3)

Publication Number Publication Date
JP2020511536A JP2020511536A (ja) 2020-04-16
JP2020511536A5 true JP2020511536A5 (OSRAM) 2021-04-30
JP7178375B2 JP7178375B2 (ja) 2022-11-25

Family

ID=63445929

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019572352A Active JP7178375B2 (ja) 2017-03-13 2018-03-12 デュアルmagl及びfaahインヒビター
JP2022014178A Active JP7781660B2 (ja) 2017-03-13 2022-02-01 デュアルmagl及びfaahインヒビター
JP2022105683A Active JP7440572B2 (ja) 2017-03-13 2022-06-30 デュアルmagl及びfaahインヒビター
JP2024020785A Pending JP2024056887A (ja) 2017-03-13 2024-02-15 デュアルmagl及びfaahインヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022014178A Active JP7781660B2 (ja) 2017-03-13 2022-02-01 デュアルmagl及びfaahインヒビター
JP2022105683A Active JP7440572B2 (ja) 2017-03-13 2022-06-30 デュアルmagl及びfaahインヒビター
JP2024020785A Pending JP2024056887A (ja) 2017-03-13 2024-02-15 デュアルmagl及びfaahインヒビター

Country Status (31)

Country Link
US (4) US10350205B2 (OSRAM)
EP (3) EP4424683A3 (OSRAM)
JP (4) JP7178375B2 (OSRAM)
KR (3) KR20250016458A (OSRAM)
CN (5) CN110709084A (OSRAM)
AR (2) AR111271A1 (OSRAM)
AU (3) AU2018236161B9 (OSRAM)
CA (1) CA3056076A1 (OSRAM)
CL (1) CL2019002583A1 (OSRAM)
CO (1) CO2019009932A2 (OSRAM)
DK (1) DK3595665T3 (OSRAM)
EA (1) EA201991898A1 (OSRAM)
EC (1) ECSP19066721A (OSRAM)
ES (1) ES2994239T3 (OSRAM)
FI (1) FI3595665T3 (OSRAM)
HR (1) HRP20241558T1 (OSRAM)
HU (1) HUE069115T2 (OSRAM)
IL (3) IL311446B2 (OSRAM)
LT (1) LT3595665T (OSRAM)
MX (1) MX2022006862A (OSRAM)
NZ (1) NZ756915A (OSRAM)
PL (1) PL3595665T3 (OSRAM)
PT (1) PT3595665T (OSRAM)
RS (1) RS66192B1 (OSRAM)
SA (2) SA523450367B1 (OSRAM)
SG (1) SG11201908159QA (OSRAM)
SI (1) SI3595665T1 (OSRAM)
SM (1) SMT202400468T1 (OSRAM)
TW (2) TWI874919B (OSRAM)
WO (1) WO2018169880A1 (OSRAM)
ZA (1) ZA201905934B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP4424683A3 (en) * 2017-03-13 2024-11-06 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
MA53607B1 (fr) * 2018-09-13 2025-05-30 Celgene Corporation (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
JP2023158388A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機
JP2023158385A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機
JP2023158387A (ja) * 2022-04-18 2023-10-30 株式会社三洋物産 遊技機

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636187A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
EP1636207A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
JP2006088075A (ja) * 2004-09-27 2006-04-06 Kubota Corp 脱臭装置
EP1849773B1 (en) * 2005-02-17 2013-10-16 Astellas Pharma Inc. Piperazine derivatives for the treatment of urinary incontinence and pain
AU2006227776A1 (en) 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
CA2743861A1 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
US8461159B2 (en) * 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2010141817A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
MX2012008801A (es) * 2010-01-28 2012-08-17 Merck Sharp & Dohme Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones.
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
NZ708350A (en) 2012-11-20 2016-08-26 Merial Inc Anthelmintic compounds and compositions and method of using thereof
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
WO2015116774A1 (en) * 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
BR112018000041A2 (pt) * 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
EP4424683A3 (en) 2017-03-13 2024-11-06 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok

Similar Documents

Publication Publication Date Title
JP2020511536A5 (OSRAM)
SI2961736T1 (en) Histone demethylase inhibitors
JP2020169171A5 (OSRAM)
JP2020529994A5 (OSRAM)
JP2018530549A5 (OSRAM)
JP2019507111A5 (OSRAM)
JP2013010792A5 (OSRAM)
JP2018021051A5 (OSRAM)
JP2020532547A5 (OSRAM)
JP2008526999A5 (OSRAM)
JP2013502430A5 (OSRAM)
JP2017531020A5 (OSRAM)
JP2015509535A5 (OSRAM)
JP2013532652A5 (OSRAM)
JP2019500387A5 (OSRAM)
JP2020507589A5 (OSRAM)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2013532668A5 (OSRAM)
JP2019516739A5 (OSRAM)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2019505529A5 (OSRAM)
JP2007504235A5 (OSRAM)
JP2019520344A5 (OSRAM)
JPWO2023099592A5 (OSRAM)
JP2019529460A5 (OSRAM)